These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22977971)

  • 21. [Molecular-cytogenetic monitoring of different regimens of treatment in patients with chronic myeloid leukemia].
    Diachenko LV; Zakharova AV; Aseeva EA; Turkina AG; Khoroshko ND; Vodinskaia LA; Udovichenko AI; Domracheva EV
    Ter Arkh; 2004; 76(7):41-4. PubMed ID: 15379126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A molecular cytogenetic study on chromosome anomalies of chronic myeloid leukemia].
    Zhu B; Shen X; Li C; Lai X; Li Y; Shi K; Feng H; Wang R
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Apr; 17(2):116-8. PubMed ID: 10751535
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimal residual disease in chronic myeloid leukaemia.
    Cross NC
    Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interphase fluorescence in situ hybridization studies for the detection of 9q34 deletions in chronic myelogenous leukemia: a practical approach to clinical diagnosis.
    Aoun P; Wiggins M; Pickering D; Foran J; Rasheed H; Pavletic SZ; Sanger W
    Cancer Genet Cytogenet; 2004 Oct; 154(2):138-43. PubMed ID: 15474149
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High reliability and sensitivity of the BCR/ABL1 D-FISH test for the detection of BCR/ABL rearrangements.
    Pelz AF; Kröning H; Franke A; Wieacker P; Stumm M
    Ann Hematol; 2002 Mar; 81(3):147-53. PubMed ID: 11904740
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Application of fluorescence in situ hybridization technique in diagnosis of variant Ph chromosome translocation and Ph-negative chronic myelocytic leukemia].
    Jing Y; Jiang F; Lin S; Wang FT; Fang MY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):563-6. PubMed ID: 20931538
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic myeloid leukemia: Relevance of cytogenetic and molecular assays.
    Bennour A; Saad A; Sennana H
    Crit Rev Oncol Hematol; 2016 Jan; 97():263-74. PubMed ID: 26412717
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a review.
    An X; Tiwari AK; Sun Y; Ding PR; Ashby CR; Chen ZS
    Leuk Res; 2010 Oct; 34(10):1255-68. PubMed ID: 20537386
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Fluorescent in situ hybridization in the diagnosis, prognosis, and treatment monitoring of chronic myeloid leukemia.
    Landstrom AP; Tefferi A
    Leuk Lymphoma; 2006 Mar; 47(3):397-402. PubMed ID: 16396761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Diagnostic and prognostic cytogenetics of chronic myeloid leukaemia: an update.
    Molica M; Massaro F; Breccia M
    Expert Rev Mol Diagn; 2017 Nov; 17(11):1001-1008. PubMed ID: 28930482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chronic myelogenous leukemia: laboratory diagnosis and monitoring.
    Wang YL; Bagg A; Pear W; Nowell PC; Hess JL
    Genes Chromosomes Cancer; 2001 Oct; 32(2):97-111. PubMed ID: 11550277
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chronic myeloid leukemia: molecular monitoring in clinical practice.
    Branford S
    Hematology Am Soc Hematol Educ Program; 2007; ():376-83. PubMed ID: 18024654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).
    Roche-Lestienne C; Boudry-Labis E; Mozziconacci MJ
    Ann Biol Clin (Paris); 2016 Oct; 74(5):511-515. PubMed ID: 27477825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current management of CML patients: Summary of the Italian Consensus Meeting held in Rome, April 11-12, 2013.
    Breccia M; Alimena G; Baccarani M; Bocchia M; Di Raimondo F; Gambacorti-Passerini C; Gozzini A; Morra E; Pane F; Pregno P; Rege-Cambrin G; Rosti G; Specchia G; Vigneri P; Saglio G
    Crit Rev Oncol Hematol; 2014 Jun; 90(3):181-9. PubMed ID: 24405858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. How I monitor residual disease in chronic myeloid leukemia.
    Radich JP
    Blood; 2009 Oct; 114(16):3376-81. PubMed ID: 19661271
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Incidence of chronic myeloid leukemia in Calgary, Alberta, Canada.
    Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
    BMC Res Notes; 2018 Nov; 11(1):780. PubMed ID: 30382890
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Managing chronic myeloid leukemia: a coordinated team care perspective.
    Holloway S; Lord K; Bethelmie-Bryan B; Shepard MW; Neely J; McLemore M; Reddy SK; Montero A; Jonas WS; Gladney SP; Khanwani SL; Reddy SC; Lahiry AK; Heffner LT; Winton E; Arellano M; Khoury HJ
    Clin Lymphoma Myeloma Leuk; 2012 Apr; 12(2):88-93. PubMed ID: 22154234
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On the Power of Additional and Complex Chromosomal Aberrations in CML.
    Greulich-Bode KM; Heinze B
    Curr Genomics; 2012 Sep; 13(6):471-6. PubMed ID: 23449041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Our experience in the treatment of Malignant Fibrous Hystiocytoma of the larynx: clinical diagnosis, therapeutic approach and review of literature.
    Testa D; Motta S; Marcuccio G; Paccone M; Rocca A; Ilardi G; Tafuri D; Mesolella M; Motta G
    Open Med (Wars); 2016; 11(1):208-214. PubMed ID: 28352796
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.